Search results for "Hematologi"

showing 10 items of 194 documents

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

2010

AbstractChanging definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.6…

Malemedicine.medical_specialtyPathologyChildhood leukemiaHematologic malignant; Europe; morphologic subtype; international comparison; population-based cancer registry.ImmunologyPopulationUNITED-STATESALCOHOLBiochemistryNOMyelodysplastic–myeloproliferative diseasesInternal medicineEpidemiologymorphologymedicineLYMPHOMAHumansEPIDEMIOLOGYRegistriesEXPOSUREeducationRISKeducation.field_of_studyTOBACCOhaematologic malignanciesbusiness.industryIncidence (epidemiology)IncidenceleukemiaMyeloid leukemiaCell BiologyHematologyHematologic malignancies; morphology; Europe.Plasma cell neoplasmmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesLymphomaEuropeCANCER INCIDENCEHematologic Neoplasmscancer incidence tobacco alcohol epidemiology leukemia risk exposureCHILDHOOD LEUKEMIAHematologic malignanciesFemalebusiness
researchProduct

Feasibility of an exercise programme in elderly patients undergoing allogeneic stem cell transplantation - a pilot study

2015

It has been demonstrated that physical exercise benefits younger patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). We designed a prospective pilot study investigating whether elderly patients (>60 years) would also be able to participate in such a programme. It consisted of physiotherapist-supervised alternating endurance and resistance workouts on 6 of 7 days a week. Sixteen consecutive patients undergoing allo-HSCT were enrolled into the study. The median age was 64.5 years. Twelve patients participated in the programme until the time of discharge (75%) from the transplant unit. Therefore, the predefined criteria regarding feasibility were met. The reaso…

Malemedicine.medical_specialtyPopulationPilot ProjectsPhysical exercise03 medical and health sciences0302 clinical medicineQuality of lifeEndurance trainingHumansTransplantation HomologousMedicineMuscle StrengthProspective StudiesMuscle SkeletalAdverse effecteducationAgededucation.field_of_studybusiness.industryHematopoietic Stem Cell TransplantationMiddle AgedExercise TherapyExercise programmeTransplantationOncologyHematologic Neoplasms030220 oncology & carcinogenesisQuality of LifePhysical therapyFeasibility StudiesPatient ComplianceFemaleStem cellbusiness030215 immunologyEuropean Journal of Cancer Care
researchProduct

Vitamin C supplementation does not improve hypoxia-induced erythropoiesis.

2012

Martinez-Bello,Vladimir E., Fabian Sanchis-Gomar, Daniel Martinez-Bello, Gloria Olaso-Gonzalez, Mari Carmen Gomez-Cabrera, and Jose Viña. Vitamin C Supplementation Does Not Improve Hypoxia-Induced Erythropoiesis. High Alt Med Biol 13:269–274, 2012.—Hypoxia induces reactive oxygen species production. Supplements with antioxidant mixtures can compensate for the decline in red cell membrane stability following intermittent hypobaric hypoxia by decreasing protein and lipid oxidation. We aimed to determine whether supplementation with vitamin C is implicated in the regulation of erythropoiesis and in the oxygen-carrying capacity of the blood, and also whether antioxidant supplementation prevents…

Malemedicine.medical_specialtyScientific ArticlesAntioxidantPhysiologymedicine.medical_treatmentAscorbic AcidHematocritBiologyProtein oxidationAntioxidantsDrug Administration ScheduleRandom AllocationLipid oxidationInternal medicineMalondialdehydemedicineAnimalsErythropoiesisRats WistarHypoxiaHematologic Testsmedicine.diagnostic_testVitamin CPublic Health Environmental and Occupational HealthIntermittent hypoxiaGeneral MedicineBlood ProteinsHypoxia (medical)RatsOxidative StressEndocrinologyBiochemistryDietary SupplementsErythropoiesismedicine.symptomOxidation-ReductionBiomarkersHigh altitude medicinebiology
researchProduct

Current limitations of the Athlete's Biological Passport use in sports.

2011

The Athletes Biological Passport (ABP) has received both criticisms and support during this year. In a recent issue of The Lancet, Michael Wozny considered that the use of the ABP makes it more difficult to take banned substances and that it was successfully used against the Italian elite cyclist Franco Pellizotti. After that, Italy's anti-doping tribunal considered that there was not enough evidence to prove manipulation of his own blood profile in Pellizotti's case. However, the UCI appealed to the Court of Arbitration for Sport (CAS) that sanctioned Pellizotti with a suspension of 2 years. Since its implementation, some problems have emerged. From 2010 to date, a large number of reports …

Malemedicine.medical_specialtyTime Factorsgenetic structuresClinical BiochemistryApplied psychologymedicineHumansDoping in SportsMetabolic energyHematologic TestsbiologyAthletesbusiness.industryBiochemistry (medical)General MedicineTechnical documentationbiology.organism_classificationTransparency (behavior)SurgeryTribunalAthletesEliteArbitrationbusinessBlood Chemical AnalysisClinical chemistry and laboratory medicine
researchProduct

The hypothetical role of congenital hypotonia in the development of early coronoid hyperplasia

2012

Abstract Background Coronoid hyperplasia (CH) is an abnormal bony elongation of a histologically normal coronoid process. Its definitive cause remains unknown. Objectives To analyze the possible implication of congenital hypotonia in the pathogenesis of early coronoid overgrowth. Patients and methods Two infants with congenital hypotonia were evaluated for limited mouth aperture. Bilateral CH was diagnosed. Transoral coronoidectomy was followed by an early dynamic physiotherapy program. Results Significant improvement of maximum interincisal opening was achieved. The review of the scientific literature proved the diagnosis of CH in the infant age group is extremely unusual and the etiology …

Malemedicine.medical_specialtymedicine.medical_treatmentMandibleAspiration pneumoniaTracheostomySwallowingmedicineHumansAbnormalities MultipleRange of Motion ArticularArthrogryposisGastrostomyHyperplasiabusiness.industryInfantHyperplasiamedicine.diseaseHematologic DiseasesMusculoskeletal ManipulationsGastrostomySurgerymedicine.anatomical_structureVestibular DiseasesOtorhinolaryngologyFaceMasticatory MusclesFailure to thriveSuprahyoid musclesEtiologyMuscle HypotoniaSurgeryOral Surgerymedicine.symptomChokingbusinessFollow-Up StudiesJournal of Cranio-Maxillofacial Surgery
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct

Antiproliferative Effects of St. John’s Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies

2021

Hypericumis a widely present plant, and extracts of its leaves, flowers, and aerial elements have been employed for many years as therapeutic cures for depression, skin wounds, and respiratory and inflammatory disorders. Hypericum also displays an ample variety of other biological actions, such as hypotensive, analgesic, anti-infective, anti-oxidant, and spasmolytic abilities. However, recent investigations highlighted that this species could be advantageous for the cure of other pathological situations, such as trigeminal neuralgia, as well as in the treatment of cancer. This review focuses on the in vitro and in vivo antitumor effects of St. John’s Wort (Hypericum perforatum), its derivat…

MyeloidAngiogenesisDrug Evaluation PreclinicalReviewPharmacologylcsh:Chemistrychemistry.chemical_compoundhyperforinDrug InteractionsMyeloid CellsLymphocyteslcsh:QH301-705.5SpectroscopybiologyapoptosisleukemiaHypericum perforatumGeneral MedicineComputer Science ApplicationsHypericinLeukemiamedicine.anatomical_structurephotodynamic therapyHematologic NeoplasmsHypericumHypericumSt. John’s wortlymphomaCatalysisInorganic ChemistryStructure-Activity Relationshipmultidrug resistanceIn vivoCell Line TumormedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyCell ProliferationPlant Extractsbusiness.industryOrganic Chemistry<i>Hypericum</i>biology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicApoptosis; Hyperforin; Hypericin; Hypericum; Leukemia; Lymphoma; Mul-tidrug resistance; Photodynamic therapy; St. John’s wort; Animals; Antineoplastic Agents Phytogenic; Apoptosis; Cell Line Tumor; Cell Proliferation; Drug Evaluation Preclinical; Drug Interactions; Drug Resistance Neoplasm; Hematologic Neoplasms; Humans; Hypericum; Lymphocytes; Myeloid Cells; Plant Extracts; Structure-Activity RelationshipHyperforinchemistrylcsh:Biology (General)lcsh:QD1-999Drug Resistance NeoplasmhypericinbusinessInternational Journal of Molecular Sciences
researchProduct

Special Situations in APL

2017

The introduction of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) as the mainstay therapy of acute promyelocytic leukemia (APL) has drastically changed the outcome of this hematologic malignancy into one of the first to receive a targeted treatment. Using frontline treatment strategies including these agents in combination with standard cytotoxic drugs has provided outstanding therapeutic results in most patients. In spite of the achievement of brilliant results in the majority of patients, some special situations still require the implementation of changes from the conventional therapeutic approach. In this chapter, we will review and discuss the management of APL in older and …

OncologyAcute promyelocytic leukemiamedicine.medical_specialtybusiness.industryGenetic variantsmedicine.diseaseLeukemiachemistry.chemical_compoundTherapeutic approachchemistryOlder patientsInternal medicinemedicineHematologic malignancyTreatment strategyArsenic trioxidebusiness
researchProduct

Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.

2012

Long-term population-based survival data detailed by cancer subtype are important to measure the overall outcomes of malignancy managements. We provide net survival estimates at 1, 3, 5 and 10-year postdiagnosis on 37,549 hematological malignancy (HM) patients whose ages were >15 years, diagnosed between 1989 and 2004 and actively followed until 2008 by French population-based cancer registries. These are, to our knowledge, the first unbiased estimates of 10-year net survival in HMs detailed by subtypes. HMs were classified according to the International Classification of Diseases-Oncology 3. Net survival was estimated with the unbiased Pohar-Perme method. The results are reported by sex an…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationFollicular lymphomaMalignancyAge DistributionBiasInternal medicinemedicineHumansRegistriesSex DistributioneducationAgededucation.field_of_studyLeukemiaModels Statisticalbusiness.industryMortality rateLymphoma Non-HodgkinCancerMiddle Agedmedicine.diseasePrognosisHodgkin DiseaseLymphomaCancer registryOncologyHematologic NeoplasmsMyelodysplastic SyndromesImmunologyFemaleFrancebusinessChronic myelogenous leukemiaInternational journal of cancer
researchProduct